The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies
7.5
来源：
Nature
关键字：
in silico screening
发布时间：
2025-10-10 19:37
摘要：
Salvinorin A, a potent kappa opioid receptor agonist, demonstrates therapeutic potential in treating pain, addiction, and cerebrovascular diseases, although its clinical use is hampered by side effects, particularly in depression. This systematic review synthesizes preclinical findings, revealing both beneficial effects and toxicity concerns. The identification of 16 analogues with improved safety profiles suggests a promising avenue for future research and clinical application, particularly in neuropsychiatric disorders.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
Salvinorin A has been tested in animal models of pain, cerebrovascular insults, addiction, and depression.
It exhibited anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects.
The development of novel analogues could address challenges related to its side effect profile.
真实性检查
否
AI评分总结
Salvinorin A, a potent kappa opioid receptor agonist, demonstrates therapeutic potential in treating pain, addiction, and cerebrovascular diseases, although its clinical use is hampered by side effects, particularly in depression. This systematic review synthesizes preclinical findings, revealing both beneficial effects and toxicity concerns. The identification of 16 analogues with improved safety profiles suggests a promising avenue for future research and clinical application, particularly in neuropsychiatric disorders.